Trial Profile
A Compassionate use program with Trifluridine/Tipiracil (TAS-102) in patients with a pretreated metastatic colorectal cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jun 2017
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 05 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2017 New trial record